Novartis AG (LON:0K9E)

Market Cap	207.93B +28.7%
Revenue (ttm)	41.94B +12.9%
Net Income	10.71B -18.2%
EPS	5.43 -14.9%
Shares Out	n/a
PE Ratio	19.42
Forward PE	17.33
Dividend	2.61 (1.77%)
Ex-Dividend Date	Mar 12, 2025

Volume	281
Average Volume	5,846
Open	147.85
Previous Close	149.49
Day's Range	147.85 - 149.98
52-Week Range	97.51 - 153.60
Beta	0.45
RSI	64.03
Earnings Date	Feb 4, 2026

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 75,883
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K9E

Financial Performance

In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.

Financial numbers in USD